Sing P. Chan

Array ( [id] => 6765250 [patent_doc_number] => 20030099648 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-05-29 [patent_title] => 'Interferon-gamma-binding molecules for treating septic shock, cachexia, immune diseases and skin disorders' [patent_app_type] => new [patent_app_number] => 10/071485 [patent_app_country] => US [patent_app_date] => 2002-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 33 [patent_figures_cnt] => 33 [patent_no_of_words] => 30534 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0099/20030099648.pdf [firstpage_image] =>[orig_patent_app_number] => 10071485 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5905028 [patent_doc_number] => 20020141990 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-10-03 [patent_title] => 'Anti-RSV human monoclonal antibodies' [patent_app_type] => new [patent_app_number] => 10/066895 [patent_app_country] => US [patent_app_date] => 2002-02-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 15564 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0141/20020141990.pdf [firstpage_image] =>[orig_patent_app_number] => 10066895 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6688348 [patent_doc_number] => 20030032073 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-02-13 [patent_title] => 'Method for diagnosis and therapy of Hodgkin\'s lymphomas' [patent_app_type] => new [patent_app_number] => 10/052641 [patent_app_country] => US [patent_app_date] => 2002-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 8638 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0032/20030032073.pdf [firstpage_image] =>[orig_patent_app_number] => 10052641 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 731454 [patent_doc_number] => 07037498 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2006-05-02 [patent_title] => 'Antibodies to insulin-like growth factor I receptor' [patent_app_type] => utility [patent_app_number] => 10/038591 [patent_app_country] => US [patent_app_date] => 2002-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 29 [patent_no_of_words] => 36269 [patent_no_of_claims] => 130 [patent_no_of_ind_claims] => 16 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/037/07037498.pdf [firstpage_image] =>[orig_patent_app_number] => 10038591 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5921149 [patent_doc_number] => 20020114814 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-08-22 [patent_title] => 'CTLA4-Cgamma4 fusion proteins' [patent_app_type] => new [patent_app_number] => 10/027075 [patent_app_country] => US [patent_app_date] => 2001-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 24427 [patent_no_of_claims] => 91 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0114/20020114814.pdf [firstpage_image] =>[orig_patent_app_number] => 10027075 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6462250 [patent_doc_number] => 20020150573 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-10-17 [patent_title] => 'Anti-Igalpha-Igbeta antibody for lymphoma therapy' [patent_app_type] => new [patent_app_number] => 10/038107 [patent_app_country] => US [patent_app_date] => 2001-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13326 [patent_no_of_claims] => 35 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0150/20020150573.pdf [firstpage_image] =>[orig_patent_app_number] => 10038107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6688370 [patent_doc_number] => 20030032095 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-02-13 [patent_title] => 'Novel nucleic acid sequences encoding human semaphorin-like polypeptides' [patent_app_type] => new [patent_app_number] => 10/002050 [patent_app_country] => US [patent_app_date] => 2001-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 38328 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0032/20030032095.pdf [firstpage_image] =>[orig_patent_app_number] => 10002050 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6838845 [patent_doc_number] => 20030036185 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-02-20 [patent_title] => 'Novel amino acid sequences for human kidney cadherin-like polypeptides' [patent_app_type] => new [patent_app_number] => 10/002304 [patent_app_country] => US [patent_app_date] => 2001-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 37 [patent_figures_cnt] => 37 [patent_no_of_words] => 38319 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0036/20030036185.pdf [firstpage_image] =>[orig_patent_app_number] => 10002304 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6473243 [patent_doc_number] => 20020151494 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-10-17 [patent_title] => 'Novel amino acid sequences for human semaphorin-like polypeptides' [patent_app_type] => new [patent_app_number] => 10/003152 [patent_app_country] => US [patent_app_date] => 2001-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 38242 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0151/20020151494.pdf [firstpage_image] =>[orig_patent_app_number] => 10003152 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6756541 [patent_doc_number] => 20030004318 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-01-02 [patent_title] => 'High affinity humanized anti-tag-72 monoclonalantibodies' [patent_app_type] => new [patent_app_number] => 09/998817 [patent_app_country] => US [patent_app_date] => 2001-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 13469 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0004/20030004318.pdf [firstpage_image] =>[orig_patent_app_number] => 09998817 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1166031 [patent_doc_number] => 06752990 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2004-06-22 [patent_title] => 'High affinity humanized anti-TAG-72 monoclonal antibodies' [patent_app_type] => B2 [patent_app_number] => 10/040997 [patent_app_country] => US [patent_app_date] => 2001-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 16320 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/752/06752990.pdf [firstpage_image] =>[orig_patent_app_number] => 10040997 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1179151 [patent_doc_number] => 06737061 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2004-05-18 [patent_title] => 'High affinity humanized anti-TAG-72 monoclonal antibodies' [patent_app_type] => B2 [patent_app_number] => 09/999025 [patent_app_country] => US [patent_app_date] => 2001-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 16312 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 201 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/737/06737061.pdf [firstpage_image] =>[orig_patent_app_number] => 09999025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6540622 [patent_doc_number] => 20020193574 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-12-19 [patent_title] => 'High affinity humanized anti-tag-72 monoclonalantibodies' [patent_app_type] => new [patent_app_number] => 09/999040 [patent_app_country] => US [patent_app_date] => 2001-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 13254 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0193/20020193574.pdf [firstpage_image] =>[orig_patent_app_number] => 09999040 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6736219 [patent_doc_number] => 20030013854 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-01-16 [patent_title] => 'High affinity humanized anti-TAG-72 monoclonalantibodies' [patent_app_type] => new [patent_app_number] => 09/999021 [patent_app_country] => US [patent_app_date] => 2001-10-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 13239 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0013/20030013854.pdf [firstpage_image] =>[orig_patent_app_number] => 09999021 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6611730 [patent_doc_number] => 20020064528 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-05-30 [patent_title] => 'Antibodies specific to KDR and uses thereof' [patent_app_type] => new [patent_app_number] => 09/976787 [patent_app_country] => US [patent_app_date] => 2001-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 8771 [patent_no_of_claims] => 61 [patent_no_of_ind_claims] => 31 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0064/20020064528.pdf [firstpage_image] =>[orig_patent_app_number] => 09976787 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6415543 [patent_doc_number] => 20020183495 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-12-05 [patent_title] => 'High affinity humanized anti-CEA monoclonal antibodies' [patent_app_type] => new [patent_app_number] => 09/974051 [patent_app_country] => US [patent_app_date] => 2001-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 13112 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0183/20020183495.pdf [firstpage_image] =>[orig_patent_app_number] => 09974051 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6774833 [patent_doc_number] => 20030018171 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-01-23 [patent_title] => 'High affinity humanized anti-CEA monoclonal antibodies' [patent_app_type] => new [patent_app_number] => 09/974498 [patent_app_country] => US [patent_app_date] => 2001-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 13094 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0018/20030018171.pdf [firstpage_image] =>[orig_patent_app_number] => 09974498 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5789431 [patent_doc_number] => 20020161178 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-10-31 [patent_title] => 'Novel DKR polypeptides' [patent_app_type] => new [patent_app_number] => 09/976736 [patent_app_country] => US [patent_app_date] => 2001-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 22837 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0161/20020161178.pdf [firstpage_image] =>[orig_patent_app_number] => 09976736 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6571392 [patent_doc_number] => 20020165387 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-11-07 [patent_title] => 'High affinity humanized anti-CEA monoclonal antibodies' [patent_app_type] => new [patent_app_number] => 09/974052 [patent_app_country] => US [patent_app_date] => 2001-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 13087 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0165/20020165387.pdf [firstpage_image] =>[orig_patent_app_number] => 09974052 [rel_patent_id] =>[rel_patent_doc_number] =>)